Could Aficamten Give Cytokinetics the First Approved nHCM Treatment?

Summary

The article discusses whether Cytokinetics' aficamten could become the first approved treatment for non-obstructive hypertrophic cardiomyopathy (nHCM). No specific approval decision, date, or trial outcome data is provided in the article excerpt.